학술논문

SARS-CoV-2 Variant Exposures Elicit Antibody Responses With Differential Cross-Neutralization of Established and Emerging Strains Including Delta and Omicron
Document Type
article
Source
The Journal of Infectious Diseases. 225(11)
Subject
Medical Microbiology
Biomedical and Clinical Sciences
Vaccine Related
Coronaviruses Vaccines
Coronaviruses
Infectious Diseases
Prevention
Emerging Infectious Diseases
Immunization
2.1 Biological and endogenous factors
Aetiology
Good Health and Well Being
Antibodies
Neutralizing
Antibodies
Viral
Antibody Formation
COVID-19
Humans
SARS-CoV-2
Spike Glycoprotein
Coronavirus
neutralization
variant
B
1
617
2
529
vaccination
natural infection
antibody escape
immune exposure
B.1.1.529
B.1.617.2
Biological Sciences
Medical and Health Sciences
Microbiology
Biological sciences
Biomedical and clinical sciences
Health sciences
Language
Abstract
The wide spectrum of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with phenotypes impacting transmission and antibody sensitivity necessitates investigation of immune responses to different spike protein versions. Here, we compare neutralization of variants of concern, including B.1.617.2 (delta) and B.1.1.529 (omicron), in sera from individuals exposed to variant infection, vaccination, or both. We demonstrate that neutralizing antibody responses are strongest against variants sharing certain spike mutations with the immunizing exposure, and exposure to multiple spike variants increases breadth of variant cross-neutralization. These findings contribute to understanding relationships between exposures and antibody responses and may inform booster vaccination strategies.